Drugs / MEDI0639
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01577745 | Apr 2012 → Dec 2015 | cancer | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI0639 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01577745 ↗ |
| Action | Inhibit | “blocks its ability to bind to and activate signaling through the Notch receptors.” NCT01577745 ↗ |
| Modality | Monoclonal antibody | “MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody.” NCT01577745 ↗ |
| Route | Intravenous | “60-minute intravenous (IV) infusion” NCT01577745 ↗ |
| Target | DLL4 | “MEDI0639 selectively binds to DLL4” NCT01577745 ↗ |